Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.3390
-0.0010 (-0.29%)
At close: Dec 5, 2025, 4:00 PM EST
0.3325
-0.0065 (-1.92%)
After-hours: Dec 5, 2025, 6:18 PM EST
Akari Therapeutics, Employees
As of December 31, 2024, Akari Therapeutics, had 9 total employees, including 8 full-time and 1 part-time employees. The number of employees decreased by 3 or -25.00% compared to the previous year.
Employees
9
Change (1Y)
-3
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,752,444
Market Cap
12.12M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AKTX News
- 1 day ago - Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment - GlobeNewsWire
- 10 days ago - Akari Therapeutics Announces Release of the Next CEO Corner Segment - GlobeNewsWire
- 17 days ago - Akari Therapeutics, Plc (AKTX) Shareholder/Analyst Call Transcript - Seeking Alpha
- 17 days ago - Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer - GlobeNewsWire
- 25 days ago - Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors - GlobeNewsWire
- 4 weeks ago - Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available - GlobeNewsWire
- 5 weeks ago - Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP - GlobeNewsWire
- 6 weeks ago - Akari Therapeutics Announces Launch of CEO Corner Platform - GlobeNewsWire